CooperCompanies’ first quarter results reflected ongoing operational execution and product innovation, but the market responded negatively as concerns mounted over inventory headwinds and softening demand in key segments. CEO Al White pointed to strong organic revenue growth in daily silicone hydrogel lenses and surgical devices, but acknowledged that channel inventory reductions and tighter clinic spending, particularly in fertility, weighed on reported results. Management described the global operating environment as “more complex” and cited persistent pressures from both distributors and end customers managing inventory more conservatively.

Is now the time to buy COO? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions CooperCompanies’s Q1 Earnings Call

• Jeffrey Johnson (Baird) asked about discrepancies in reported growth versus underlying demand, focusing on the impact of channel inventory dynamics. CEO Al White explained that fitting data remains strong, but revenue is pressured as distributors and consumers manage inventory more cautiously.
• Issie Kirby (Redburn Atlantic) questioned the rationale behind lowered market growth guidance for Vision Care. White attributed the change to generalized market softness rather than specific pricing or volume declines, and highlighted the mix shift toward daily lenses.
• Larry Biegelsen (Wells Fargo) explored consumer purchasing patterns, noting a shift to smaller supply purchases. White confirmed that this behavior is contributing to reduced channel inventory and softer reported revenue, despite stable or improving fitting trends.
• Craig Bijou (Bank of America) probed CooperCompanies’ confidence in outperforming the market despite guidance reductions. White cited strong MyDay and MiSight demand, as well as expanding private label deals, as drivers of expected share gains.
• Joanne Wuensch (Citibank) asked whether updated guidance reflected actual market trends or management conservatism. White acknowledged that the new outlook incorporates both observed market tightening and a more prudent approach given macro uncertainty.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will track (1) the pace of adoption for new MyDay and MiSight offerings, especially as fitting set and promotional strategies roll out; (2) signs of stabilization or improvement in fertility clinic demand, particularly in Asia-Pacific; and (3) the company’s ability to maintain margin expansion amid tariff and currency headwinds. Execution on manufacturing efficiency and product launches will also be critical for sustaining growth.

CooperCompanies currently trades at $71.50, down from $80.01 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.